{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:53:45Z","timestamp":1790988825415,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009009","name":"Novartis Pharmaceuticals Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"DOI":"10.1007\/s41669-026-00674-7","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:06:53Z","timestamp":1790942813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness Analysis of Ribociclib plus an Aromatase Inhibitor (AI) Versus AI Alone in the Adjuvant Treatment of Stage II and III Pre- and Postmenopausal Women with HR+\/HER2\u2212 Early Breast Cancer (EBC): A Canadian Payer Perspective"],"prefix":"10.1007","author":[{"given":"Dina","family":"Soliman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4818-318X","authenticated-orcid":false,"given":"Christine","family":"Brezden-Masley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7434-2263","authenticated-orcid":false,"given":"Sandeep","family":"Sehdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"El Ouagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8638-9754","authenticated-orcid":false,"given":"Natalia Sabater","family":"Anaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Stellato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talitha","family":"Vincken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"674_CR1","unstructured":"Canadian Cancer Society. Breast cancer statistics. 2024. https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/breast\/statistics."},{"key":"674_CR2","unstructured":"Surveillance Epidemiology and End Results Program. Cancer stat facts. Female breast cancer. 2023. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html."},{"key":"674_CR3","unstructured":"American Cancer Society. Treatment of breast cancer by stage. https:\/\/www.cancer.org\/cancer\/breast-cancer\/treatment\/treatment-of-breast-cancer-by-stage.html."},{"issue":"10","key":"674_CR4","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1093\/annonc\/mdz189","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(10):1674.","journal-title":"Ann Oncol"},{"key":"674_CR5","unstructured":"National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer. Version 4.2023\u2014March 23, 2023. 2023. http:\/\/nccn.org."},{"key":"674_CR6","unstructured":"Canadian Cancer Society. Treatment for early stage breast cancer. 2024. https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/breast\/treatment\/early-stage."},{"key":"674_CR7","doi-asserted-by":"publisher","unstructured":"Fasching PA, Stroyakovskiy D, Yardley DA, et al. Ribociclib plus endocrine therapy in hormone receptor\u2013positive\/ERBB2-negative early breast cancer: 4-year outcomes from the NATALEE randomized clinical trial. JAMA Oncol. 2025;11(11):1364\u201372. https:\/\/doi.org\/10.1001\/jamaoncol.2025.3700.","DOI":"10.1001\/jamaoncol.2025.3700"},{"key":"674_CR8","doi-asserted-by":"publisher","first-page":"S1207","DOI":"10.1016\/j.annonc.2024.08.2251","volume":"35","author":"PA Fasching","year":"2024","unstructured":"Fasching PA, et al. LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+\/HER2\u2212 early breast cancer (EBC): 4-year outcomes from the NATALEE trial. Ann Oncol. 2024;35:S1207.","journal-title":"Ann Oncol"},{"issue":"2","key":"674_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10549-020-05960-4","volume":"185","author":"C Brezden-Masley","year":"2021","unstructured":"Brezden-Masley C, et al. A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive\/HER2-negative breast cancer. Breast Cancer Res Treat. 2021;185(2):507\u201315.","journal-title":"Breast Cancer Res Treat"},{"key":"674_CR10","unstructured":"pan-Canadian Oncology Drug Review. Adjuvant treatment of HR-positive, HER2-negative early breast cancer, Reimbursement Recommendation Ribociclib (Kisqali). 2026."},{"key":"674_CR11","unstructured":"Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada. 2021. https:\/\/www.cadth.ca\/about-cadth\/how-we-do-it\/methods-and-guidelines\/guidelines-for-the-economic-evaluation-of-health-technologies-canada."},{"issue":"12","key":"674_CR12","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon D, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390(12):1080\u201391.","journal-title":"N Engl J Med"},{"key":"674_CR13","unstructured":"Canadian Agency for Drugs and Technologies in Health. CDA Reimbursement Review: Abemaciclib (Verzenio). 2025. https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2024\/PC0345_Final_Recommendation.pdf."},{"key":"674_CR14","unstructured":"pan-Canadian Oncology Drug Review. Final Economic Guidance Report\u2014Ribociclib (Kisqali) plus Fulvestrant for Advanced or Metastatic Breast Cancer. 2020. https:\/\/cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10195RibociclibFulvestrantMBC_fnEGR_NOREDACT-ABBREV_EC_22Apr2020_final.pdf. Accessed 20 Aug 2020."},{"key":"674_CR15","unstructured":"Jackson, C., Package \u2018flexsurv\u2019. Flexible Parametric Survival and Multi-State Models. 2016. https:\/\/cran.r-project.org\/web\/packages\/flexsurv\/flexsurv.pdf. Accessed 26 Sept 2016."},{"key":"674_CR16","doi-asserted-by":"crossref","unstructured":"Janni W, et al. Comparing the efficacy of aromatase inhibitors vs tamoxifen in hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative early breast cancer: a systematic review and trial-level meta-analysis. In: San Antonio Breast Cancer Symposium Poster P1-02-01. 2022.","DOI":"10.1158\/1538-7445.SABCS22-P1-02-01"},{"key":"674_CR17","unstructured":"National Institute of Health and Care Excellence. Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence [TA810]. 2022. https:\/\/www.nice.org.uk\/guidance\/ta810."},{"key":"674_CR18","unstructured":"National Institute of Health and Care Excellence, Committee Papers [TA632]: single technology appraisal trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer [ID1516]. https:\/\/www.nice.org.uk\/guidance\/ta632\/evidence\/committee-papers-pdf-8771187997. 2020."},{"issue":"5","key":"674_CR19","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.ijrobp.2014.12.051","volume":"91","author":"SN Hamilton","year":"2015","unstructured":"Hamilton SN, et al. Second malignancies after adjuvant radiation therapy for early stage breast cancer: is there increased risk with addition of regional radiation to local radiation? Int J Radiat Oncol Biol Phys. 2015;91(5):977\u201385.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"674_CR20","unstructured":"Statistics Canada, Life expectancy and other elements of the complete life table, single-year estimates, Canada, all provinces except Prince Edward Island. Table: 13-10-0837-01. 2022. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/cv.action?pid=1310083701."},{"key":"674_CR21","unstructured":"National Institute of Health and Care Excellence, NICE TA1086 Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence. 2025. https:\/\/www.nice.org.uk\/guidance\/ta1086."},{"key":"674_CR22","unstructured":"Fraser Morton and Jagtar Singh Nijjar. Package 'eq5d': Methods for Analysing 'EQ-5D' Data and Calculating 'EQ-5D' Index Scores. 2023. https:\/\/cran.r-project.org\/web\/packages\/eq5d\/eq5d.pdf."},{"issue":"1","key":"674_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/MLR.0000000000000447","volume":"54","author":"F Xie","year":"2016","unstructured":"Xie F, et al. A time trade-off-derived value set of the EQ-5D-5L for Canada. Med Care. 2016;54(1):98\u2013105.","journal-title":"Med Care"},{"key":"674_CR24","unstructured":"pan-Canadian Oncology Drug Review. Final Economic Guidance Report\u2014Ribociclib (Kisqali) for Metastatic Breast Cancer. 2018. https:\/\/cadth.ca\/sites\/default\/files\/pcodr\/pcodr_ribociclib_kisqali_mbc_fn_egr.pdf. Accessed 11 Apr 2019."},{"issue":"6","key":"674_CR25","doi-asserted-by":"publisher","first-page":"E155","DOI":"10.1503\/cmaj.170317","volume":"190","author":"JR Guertin","year":"2018","unstructured":"Guertin JR, Feeny D, Tarride JE. Age- and sex-specific Canadian utility norms, based on the 2013\u20132014 Canadian community health survey. CMAJ. 2018;190(6):E155\u201361.","journal-title":"CMAJ"},{"key":"674_CR26","unstructured":"DeltaPA. [Ontario] IQVIA. 2023."},{"key":"674_CR27","unstructured":"Canadian Institute for Health Information. Pharmaceutical Data Tool. 2024. https:\/\/www.cihi.ca\/en\/pharmaceutical-data-tool."},{"key":"674_CR28","unstructured":"Ontario Ministry of Health, Schedule of Benefits: Physician Services Under the Health Insurance Act (March 9, 2023 (effective April 1, 2023)). 2023."},{"key":"674_CR29","unstructured":"National Institute of Health and Care Excellence, TA612 Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab. 2019. https:\/\/www.nice.org.uk\/guidance\/ta612\/evidence."},{"key":"674_CR30","unstructured":"PAI, Survey of Canadian Physicians Regarding Treatment Patterns and Healthcare Utilization in Postmenopausal Women Receiving First-Line Treatment of HR+\/HER2\u2212 Advanced Breast Cancer. 2017."},{"issue":"6","key":"674_CR31","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/hsc.12170","volume":"23","author":"M Yu","year":"2015","unstructured":"Yu M, Guerriere DN, Coyte PC. Societal costs of home and hospital end-of-life care for palliative care patients in Ontario, Canada. Health Soc Care Community. 2015;23(6):605\u201318.","journal-title":"Health Soc Care Community"},{"key":"674_CR32","unstructured":"Statistics Canada. Consumer Price Index by product group, monthly, percentage change, not seasonally adjusted, Canada, provinces, Whitehorse, Yellowknife and Iqaluit (Table: 18-10-0004-13). 2023. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1810000413."},{"issue":"12","key":"674_CR33","doi-asserted-by":"publisher","first-page":"S261","DOI":"10.1016\/j.jval.2025.09.386","volume":"28","author":"MA Loupas","year":"2025","unstructured":"Loupas MA, Antonopoulou V, Kalogeropoulou M. PT35 cost-effectiveness analysis of ribociclib plus endocrine therapy for the treatment of HR\/HER2 early breast cancer in Greece. Value Health. 2025;28(12):S261.","journal-title":"Value Health"},{"key":"674_CR34","doi-asserted-by":"publisher","first-page":"11049","DOI":"10.1200\/JCO.2025.43.16_suppl.11049","volume":"43","author":"K Potnis","year":"2025","unstructured":"Potnis K, et al. Cost-effectiveness of ribociclib plus endocrine therapy in HR-positive, HER2-negative early breast cancer in the United States. J Clin Oncol. 2025;43:11049\u201311049.","journal-title":"J Clin Oncol"},{"issue":"11","key":"674_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105858","volume":"10","author":"J Crown","year":"2025","unstructured":"Crown J, et al. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive\/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival. ESMO Open. 2025;10(11):105858.","journal-title":"ESMO Open"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00674-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-026-00674-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00674-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:02:36Z","timestamp":1790985756000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-026-00674-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":35,"alternative-id":["674"],"URL":"https:\/\/doi.org\/10.1007\/s41669-026-00674-7","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Sandeep Sehdev previously acted as research support in advisory boards and other consultations for Novartis, Eli Lilly, AstraZeneca, Merck, Daiichi Sankyo, and Roche, and previously received speaking fees\u00a0from Novartis, Eli Lilly, AstraZeneca, Knight, Gilead, Daiichi Sankyo, and Roche. Dr. Christine Brezden-Masley received research grants and participated in clinical trials receiving funding from Pfizer, AstraZeneca, Novartis, Eli Lilly, Gilead Sciences, Astellas, Daiichi Sankyo, and Merck. Dr. Brezden-Masley also previously received speaker fees from Amgen, Pfizer, AstraZeneca, Novartis, Knight, Eli Lilly, Gilead, Astellas, BMS, Merck, Daiichi Sankyo, and Roche, and acted as a medical advisory consultant for Amgen, Pfizer, AstraZeneca, Novartis, Knight, Eli Lilly, Gilead, Astellas, BMS, Duchesnay, Merck, Daiichi Sankyo, and Roche. N. Sabater Anaya, D. Soliman,\u00a0K. El Ouagari, D. Stellato, and T. Vincken have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N. Sabater Anaya, D. Soliman,\u00a0K. El Ouagari, D. Stellato, and T. Vincken were involved with the study conception, analysis interpretation, manuscript drafting, and revision. C. Brezden-Masley, K. El Ouagari, and S. Sehdev were involved with analysis interpretation, manuscript drafting, and revision.","order":2,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article utilized secondary analyses of NATALEE trial data provided by Novartis.","order":3,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for Publication (From Participants)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}